Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ergotamine Tartrate

FDA-approved product (aerosol, metered, inhalation), marketed as Ergomar, Ergostat, Medihaler Ergotamine and 1 more.

Registered studies
10
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ergotamine Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Headache
  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ergot alkaloids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

10registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ergotamine Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ergotamine Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults

    NCT05351086 · start 2022-06-09

    Registered record
    Registry ID
    NCT05351086
    Conditions
    Healthy
    Interventions
    PUR3100; Dihydroergotamine (D.H.E 45); Matching Placebo for PUR3100; Matching Placebo for D.H.E 45
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-09
    Completion
    2022-09-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPUR3100; Dihydroergotamine (D.H.E 45); Matching Placebo for PUR3100; Matching Placebo for D.H.E 45
    PhasePhase 1
    Registry statusCompleted

  • A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

    NCT04940390 · start 2021-06-30

    Registered record
    Registry ID
    NCT04940390
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2022-10-26
    Enrolment
    1,591

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

    NCT04406649 · start 2020-09-14

    Registered record
    Registry ID
    NCT04406649
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-14
    Completion
    2023-01-16
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine
    PhasePhase 3
    Registry statusCompleted

  • A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

    NCT03901482 · start 2019-06-24

    Registered record
    Registry ID
    NCT03901482
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura
    Interventions
    Dihydroergotamine; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-24
    Completion
    2020-08-13
    Enrolment
    1,201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura
    InterventionDihydroergotamine; Placebos
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

    NCT03874832 · start 2018-09-11

    Registered record
    Registry ID
    NCT03874832
    Conditions
    Migraine With Aura; Migraine Without Aura; Migraine
    Interventions
    Dihydroergotamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-11
    Completion
    2018-11-07
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine With Aura; Migraine Without Aura; Migraine
    InterventionDihydroergotamine
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME

    NCT03384524 · start 2018-03

    Registered record
    Registry ID
    NCT03384524
    Conditions
    Diabetic Macular Edema
    Interventions
    Bromocriptine 2.5 MG; Metoprolol 25 MG; Tamsulosin 0.4 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-03
    Completion
    2019-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Macular Edema
    InterventionBromocriptine 2.5 MG; Metoprolol 25 MG; Tamsulosin 0.4 MG; Placebo
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Cupping and Serkangabin Versus Conventional Migraine Treatment

    NCT01476930 · start 2008-06

    Registered record
    Registry ID
    NCT01476930
    Conditions
    Migraine Headache
    Interventions
    cupping and serkangabin syrup; conventional migraine drug treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2011-10
    Enrolment
    391

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    Interventioncupping and serkangabin syrup; conventional migraine drug treatment
    PhasePhase 4
    Registry statusCompleted

  • Pergolide Treatment and Valvular Heart Disease

    NCT00234364 · start 2005-03

    Registered record
    Registry ID
    NCT00234364
    Conditions
    Heart Valve Diseases; Parkinson's Disease; Pergolide; Fibrosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-03
    Completion
    2007-09
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Valve Diseases; Parkinson's Disease; Pergolide; Fibrosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Treatment of Orthostatic Hypotension in Autonomic Failure

    NCT00223691 · start 2002-03

    Registered record
    Registry ID
    NCT00223691
    Conditions
    Autonomic Failure; Orthostatic Hypotension
    Interventions
    Atomoxetine; Acarbose; Pyridostigmine Bromide; Yohimbine; Midodrine HCl; placebo; Modafinil; Octreotide; water intake; Diphenhydramine Hydrochloride; Ranitidine HCL; Tranylcypromine; Ergotamine/ Caffeine; Celecoxib; Pseudoephedrine; Methylphenidate; Indomethacin; Ibuprofen; Oxymetazoline 0.05% nasal solution; Bovril; Acetazolamide; Rivastigmine tartrate; Carbidopa/levodopa; Inflatable abdominal binder; inflatable abdominal binder (sham)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-03
    Completion
    2017-01
    Enrolment
    389

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Failure; Orthostatic Hypotension
    InterventionAtomoxetine; Acarbose; Pyridostigmine Bromide; Yohimbine +21 more
    PhasePhase 1
    Registry statusCompleted

  • Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia

    NCT01408069

    Registered record
    Registry ID
    NCT01408069
    Conditions
    Tensional-type Headache
    Interventions
    MIGRANE; PARCEL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTensional-type Headache
    InterventionMIGRANE; PARCEL
    PhasePhase 3
    Registry statusWithdrawn